Dosage Form Design & Patient Compliance: Exploring ODTs as a Patient-centric Solution

Webcast

Thursday, January 27th 2022 at 11AM EST | 4PM GMT | 8AM PST In this webinar, experts provide an overview of the needs of different patient populations, and examine the common challenges leading to non-compliance. The experts also discuss how an orally dissolving tablet (ODT) provides a solution to address patient challenges and enables potentially more successful treatments.

Register free: https://www.pharmtech.com/pt_w/ODTs

Event Overview:

Medication non-compliance by patients has a significant impact on the burden of healthcare costs. The common challenges causing patient non-compliance are due to a combination of influences, including specific disease type, age, and therapy regimen. Often, the regimen may include dosage forms that are not sufficiently tailored to meet patient needs. As a result of poor medication adherence, overall treatment success lessens. To mitigate the risk of patient non-compliance, innovators should consider specific patient challenges for different disease types and the many variables in the lives of patients. In this webinar, experts provide an overview of the needs of different patient populations, and examine the common challenges leading to non-compliance. The experts also discuss how an orally dissolving tablet (ODT) provides a solution to address patient challenges and enables potentially more successful treatments.

Key Learning Objectives:

  • Overview of different patient populations and common challenges
  • Learn what influences medication adherence and the impacts of non-compliance
  • Discover how Zydis® ODT can facilitate medication adherence and help create more successful treatments

Speakers

David Elder
Principal Consultant
David P Elder Consultancy

David Elder has nearly 40 years of service within the pharmaceutical industry at Sterling, Syntext and GlaxoSmithKline. He is now an independent GMC consultant. He is a visiting professor at King’s College, London and is a member of the British Pharmacopoeia. He is a member of the Joint Pharmaceutical Analysis Group (JPAG) and the Analytical Division Council of the Royal Society of Chemistry.

Ralph Gosden
Head of Zydis Product Development
Catalent

Ralph Gosden, Head of Product Development at Catalent’s Swindon, UK site oversees Catalent’s Zydis® Fast Dissolve Tablet scale up and strategic project capabilities. In a career spanning over 20 years, Ralph has worked in all the major disciplines in pharmaceutical R&D from feasibility through scale up and validation and has extensive experience understanding formulation and process development for oral dose forms.

Register free: https://www.pharmtech.com/pt_w/ODTs